Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

20098,205 citationsJournal Articlebronze Open Access

Authors

Tony Mok · Chinese University of Hong Kong

Yi‐Long Wu

Sumitra Thongprasert · Chiang Mai University

James Chih‐Hsin Yang · National Taiwan University Hospital

Da-Tong Chu · Chinese Academy of Medical Sciences & Peking Union Medical College

Nagahiro Saijo · National Cancer Center Hospital East

Patrapim Sunpaweravong · Prince of Songkla University

Abstract

Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. (ClinicalTrials.gov number, NCT00322452.)

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 10, pp. 947-957

DOI: 10.1056/nejmoa0810699

Field-Weighted Citation Impact: 402.62